Cardiovascular endocrinology最新文献_第8页

sP-selectin is a useful biomarker for cardiovascular risk: findings from an elderly primary healthcare population sp -选择素是心血管风险的有用生物标志物:来自老年初级保健人群的发现

Cardiovascular endocrinology Pub Date : 2015-03-01 DOI: 10.1097/XCE.0000000000000042

U. Alehagen, T. Lindahl

{"title":"sP-selectin is a useful biomarker for cardiovascular risk: findings from an elderly primary healthcare population","authors":"U. Alehagen, T. Lindahl","doi":"10.1097/XCE.0000000000000042","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000042","url":null,"abstract":"Objectives sP-selectin is a marker for atherosclerosis and inflammation. It provides prognostic information on cardiovascular events, as reported in the literature. The aim of the present study was to evaluate sP-selectin as a biomarker for cardiovascular mortality in an elderly primary healthcare population, with a focus on possible sex differences. Methods The study included 437 elderly healthy participants from an epidemiological project living in a rural municipality. Clinical examination, echocardiography, and biomarker measurements were performed. All participants were followed for 5.2 years and all mortality was registered. Results sP-selectin was shown to provide significant prognostic information also when including NT-proBNP in a multivariate setting over 5 years with a hazard ratio of 3.12 (95% confidence interval 1.57–6.18) for cardiovascular mortality and a hazard ratio of 2.46 (95% confidence interval 1.39–4.34) for all-cause mortality. The addition of D-dimer to the model did not weaken the results. The sex-specific analyses showed that sP-selectin could be used in both sexes with equally good results; however, there are signs indicating possibly a worse prognosis for women with high-serum levels of sP-selectin. Conclusion sP-selectin is a prognostic biomarker for mortality in an elderly primary healthcare population. Compared with NT-proBNP, sP-selectin is at least as effective. We therefore suggest sP-selectin as an additional biomarker to be used in assessing the elderly to identify those at risk of cardiovascular events. The results presented should be considered hypothesis-generating, and warrant more research.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"36 1","pages":"22–27"},"PeriodicalIF":0.0,"publicationDate":"2015-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74506927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Newer targets and therapies for hypertension and dyslipidemia in diabetic patients 糖尿病患者高血压和血脂异常的新靶点和治疗方法

Cardiovascular endocrinology Pub Date : 2015-03-01 DOI: 10.1097/XCE.0000000000000043

W. Aronow

引用次数: 0

Metformin: new perspectives for an old antidiabetic drug 二甲双胍:一种古老的降糖药的新视角

Cardiovascular endocrinology Pub Date : 2015-03-01 DOI: 10.1097/XCE.0000000000000044

S. Popović-Pejičić, V. Soldat-Stankovic

{"title":"Metformin: new perspectives for an old antidiabetic drug","authors":"S. Popović-Pejičić, V. Soldat-Stankovic","doi":"10.1097/XCE.0000000000000044","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000044","url":null,"abstract":"There have been numerous recent developments in new and emerging treatments for type 2 diabetes (T2DM). In parallel, unanticipated new aspects of an old drug – metformin – have been described. Metformin is a well-established first-line T2DM drug, and increasing number of studies support a role for metformin in preventing T2DM in patients with impaired glucose tolerance and/or impaired fasting glucose. Nonglycemic benefits have also been ascribed to metformin, such as vascular protection, improved lipid profiles, and reduced levels of antifibrinolytic factors. An amelioration in inflammation or endothelial dysfunction has also been shown. In addition, metformin has been used in the treatment of metabolic syndrome, nonalcoholic fatty liver disease, and polycystic ovarian syndrome in insulin-resistant women. There is also a growing body of evidence, mostly in the form of retrospective clinical data and experimental studies, that suggests that metformin may be associated with a decreased risk of developing certain forms of cancer and with a reduction in cancer volume. This articles summarizes the molecular mechanisms of the action of metformin as well as potential new indications for this well-known drug.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"125 1","pages":"17–21"},"PeriodicalIF":0.0,"publicationDate":"2015-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76014936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Association of pheochromocytoma and primary hyperaldosteronism in a 50-year-old man 嗜铬细胞瘤与原发性高醛固酮增多症的关系

Cardiovascular endocrinology Pub Date : 2015-03-01 DOI: 10.1097/XCE.0000000000000040

M. Hugo, A. Cremer, P. Tauzin-Fin, P. Ballanger, P. Gosse

{"title":"Association of pheochromocytoma and primary hyperaldosteronism in a 50-year-old man","authors":"M. Hugo, A. Cremer, P. Tauzin-Fin, P. Ballanger, P. Gosse","doi":"10.1097/XCE.0000000000000040","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000040","url":null,"abstract":"The association of primary hyperaldosteronism and pheochromocytoma is very rare, but poses diagnostic and therapeutic problems exemplified in the following case. A 50-year-old man was referred for resistant and severe hypertension. Laboratory tests showed low serum potassium, primary hyperaldosteronism, and an increase in urinary norepinephrine and metanephrine. An adrenal scan indicated a nodule of the right gland of 35×30 mm with a spontaneous density of 12 HU. The initial diagnosis was that of a Conn’s adenoma. A right adrenalectomy was performed. The tissue removed was a pheochromocytoma. The postoperative course was marked by persistence of high blood pressure. On laboratory tests, levels of urinary metanephrines were normalized, but primary hyperaldosteronism was still present. Thus, the case was finally diagnosed as a bilateral adrenal hyperplasia and unilateral pheochromocytoma. Five cases of involvement of both the adrenal cortex and the medulla have been reported. The scarcity of the cases published favors a fortuitous association. However, other possibilities could be envisaged. A close relation between the cortical and medullary cells has been shown that may play an important role in the regulation of the endocrinal function. Another possibility could be stimulation by adrenaline of the release of adrenocorticotropic hormone and renin, inducing cortical hyperplasia and stimulating the secretion of aldosterone, which could become self-perpetuating. Finally, there may be a genetic predisposition to the endocrine dysplasias involving a double hormonal secretion by the adrenal gland. In conclusion, the association of pheochromocytoma and primary hyperaldosteronism can present in the same patient and needs to be considered on the basis of the clinical and biochemical findings.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"27 1","pages":"39–42"},"PeriodicalIF":0.0,"publicationDate":"2015-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82657384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endocrine aspects of pre-eclampsia 子痫前期的内分泌方面

Cardiovascular endocrinology Pub Date : 2015-03-01 DOI: 10.1097/XCE.0000000000000039

G. Currie, D. Carty, J. Connell, M. Freel

引用次数: 1

Determinants of interleukin-12 in stable ischaemic heart disease 稳定缺血性心脏病中白细胞介素-12的决定因素

Cardiovascular endocrinology Pub Date : 2014-12-01 DOI: 10.1097/XCE.0000000000000031

Iiris Salonen, K. Huttunen, M. Hirvonen, J. Dufva, K. Groundstroem, Hilkka Dufva, R. Salonen

{"title":"Determinants of interleukin-12 in stable ischaemic heart disease","authors":"Iiris Salonen, K. Huttunen, M. Hirvonen, J. Dufva, K. Groundstroem, Hilkka Dufva, R. Salonen","doi":"10.1097/XCE.0000000000000031","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000031","url":null,"abstract":"ObjectiveThe aim of this study was to determine the relation of plasma interleukin-12 (IL-12) concentration to major risk factors of atherosclerosis and other personal characteristics in well-documented, stable ischaemic heart disease (IHD) patients. The hypothesis was that IL-12 is positively associated with inflammatory markers and risk factors of atherosclerosis. Materials and methodsClinical data were collected from 51 IHD patients by a questionnaire and from basic laboratory blood tests. The association of IL-12 with the biochemical, personal, health status and lifestyle determinants was investigated by regression analysis and analysis of variance. ResultsPlasma IL-12 concentration was associated inversely with the plasma concentration of triglycerides (P=0.001) and homocysteine (P=0.04). However, IL-12 was associated directly with the concentration of high-density lipoprotein cholesterol (P=0.03). IL-12 concentration was not strongly associated with other biochemical parameters nor with the health status, medication or lifestyle determinants. ConclusionThe results suggest that, contrary to the hypothesis, IL-12 was associated inversely with plasma levels of two known risk factors of coronary atherosclerosis (triglycerides, homocysteine) in stable, statin-medicated IHD patients. The lack of association of IL-12 with high-sensitivity C-reactive protein, erythrocyte sedimentation rate and the number of inflammatory cells in blood suggests that moderately elevated IL-12 did not imply ongoing systemic inflammation in these patients. Although increased IL-12 production is a sign of proinflammatory activity, it was associated directly with the plasma high-density lipoprotein cholesterol concentration. Overall, moderately elevated plasma IL-12 concentration may even be a good sign in stable IHD patients.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"122 1","pages":"123–128"},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80223747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Role of insulin resistance in essential hypertension 胰岛素抵抗在原发性高血压中的作用

Cardiovascular endocrinology Pub Date : 2014-12-01 DOI: 10.1097/XCE.0000000000000032

R. Tarray, Sheikh Saleem, D. Afroze, Irfan Yousuf, Azhara Gulnar, B. Laway, Sawan Verma

{"title":"Role of insulin resistance in essential hypertension","authors":"R. Tarray, Sheikh Saleem, D. Afroze, Irfan Yousuf, Azhara Gulnar, B. Laway, Sawan Verma","doi":"10.1097/XCE.0000000000000032","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000032","url":null,"abstract":"IntroductionHypertension is a major health problem with widespread and sometimes devastating consequences. To confirm the role of insulin resistance and hyperinsulinemia in the pathogenesis of essential hypertension, many studies have been conducted. As no data in this regard are available from our part of the world, our study focuses onestablishing the role of insulin resistance and compensatory hyperinsulinemia in the hypertensive Kashmiri population. Materials and methodsThe study was carried out at a tertiary care hospital from December 2010 to October 2012. A total of 100 individuals aged above 18 years were recruited; 50 were newly detected cases of essential hypertension and 50 were age-matched and sex-matched normal healthy individuals. Serum insulin concentration was measured using an insulin electrochemiluminescence immunoassay. Insulin resistance was determined by HOMA-IR (homeostasis model assessment of insulin resistance). A comparison and contrast analysis of data was carried out using standard statistical methods. ResultsStatistically, the difference in mean fasting blood glucose between the two study groups was significant (P=0.0001). The mean fasting serum insulin level was 15.32±13.76 µU/ml in cases and 8.01±4.08 µU/ml in controls (reference range 2.6–24.9 µU/ml); the difference was statistically significant (P=0.001). The mean value of HOMA-IR in cases was 3.81±3.42 as compared with controls with a mean HOMA-IR value of 1.76±0.93. This difference was statistically significant (P=0.0001). ConclusionEssential hypertension is significantly associated with higher mean fasting insulin levels and insulin resistance. Hyperinsulinemia has a possible role in the pathophysiology of essential hypertension with insulin resistance being the likely predominant mechanism.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"63 1","pages":"129–133"},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84734647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Does dipeptidyl peptidase IV inhibitor increase the risk of heart failure? A cardiologist's paradox 二肽基肽酶IV抑制剂会增加心力衰竭的风险吗?心脏病专家的悖论

Cardiovascular endocrinology Pub Date : 2014-12-01 DOI: 10.1097/XCE.0000000000000036

R. Kanakia, S. Martinho, T. Patel, F. A. Arain, Manoj Panday, C. J. Saux, S. Pham, S. Bailey, R. Chilton

{"title":"Does dipeptidyl peptidase IV inhibitor increase the risk of heart failure? A cardiologist's paradox","authors":"R. Kanakia, S. Martinho, T. Patel, F. A. Arain, Manoj Panday, C. J. Saux, S. Pham, S. Bailey, R. Chilton","doi":"10.1097/XCE.0000000000000036","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000036","url":null,"abstract":"Diabetes patients have a higher burden of cardiovascular disease compared with the general population. In addition, type 2 diabetes portends a very high risk for major adverse cardiovascular events. The SAVOR trial showed that patients with documented type 2 diabetes and a previous history of, or risk factors for, cardiovascular disease had a 1-year cardiovascular event rate of 2 – 3%. Whereas in the EXAMINE trial, type 2 diabetes patients with acute coronary syndrome had a 1-year event rate between 6 and 7% after revascularization. Both of these prospective trials used new dipeptidyl peptidase IV (DPP-4) inhibitors as the treatment modality. Clinically, this class of compounds is extremely well tolerated by patients. The new DPP-4 inhibitors were promising from previous meta-analyses at reducing cardiovascular outcomes. In this article, we review literature on the cardiovascular outcomes with oral hypoglycemic agents, focusing on the two recent, large prospective trials on DDP-4 inhibitors. It is important to recognize that these trials enrolled different patients. The SAVOR trial had type 2 diabetes patients ( > 40 years old) with established cardiovascular disease or multiple cardiovascular risk factors, whereas EXAMINE trial had type 2 diabetes patients ( > 18 years old) 15 – 90 days postrevascularization for acute coronary syndrome. The primary cardiovascular endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Neither trial showed a significant cardiovascular benefit. However, neither trial showed increased cardiovascular mortality. Cardiovasc Endocrinol 3:111 – 116 © 2014 Wolters Wilkins. Cardiovascular Endocrinology 2014, 3: 111 – 116","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"17 1","pages":"111-116"},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78838517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Sex-specific differences in the effects of local androgen metabolism in the heart as an indicator for the risk of myocardial infarction 心脏局部雄激素代谢的性别差异作为心肌梗死风险的指标

Cardiovascular endocrinology Pub Date : 2014-12-01 DOI: 10.1097/XCE.0000000000000037

E. Rodenburg, J. Hofland, C. van Noord, L. Visser, A. Dehghan, M. Barbalić, A. Danser, Kim S Lawson, A. Hofman, J. Witteman, E. Boerwinkle, A. Uitterlinden, B. Stricker, F. de Jong

{"title":"Sex-specific differences in the effects of local androgen metabolism in the heart as an indicator for the risk of myocardial infarction","authors":"E. Rodenburg, J. Hofland, C. van Noord, L. Visser, A. Dehghan, M. Barbalić, A. Danser, Kim S Lawson, A. Hofman, J. Witteman, E. Boerwinkle, A. Uitterlinden, B. Stricker, F. de Jong","doi":"10.1097/XCE.0000000000000037","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000037","url":null,"abstract":"AimTestosterone influences cardiovascular risk and disease in a sex-specific manner. The more potent androgen 5&agr;-dihydrotestosterone (DHT) can be formed through conversion of testosterone by the enzyme 5&agr;-reductase. We hypothesized that, because of the presence of DHT in coronary and myocardial tissues, a sexually dimorphic effect can be observed if differences exist in genetics or mRNA expression in androgen-metabolizing enzymes. Materials and methodsmRNA levels of steroidogenic enzymes and the androgen receptor (AR) were investigated in human myocardial tissue samples. Subsequently, all participants in the baseline cohort of the Rotterdam Study (RSI) with successful genotyping and without prevalent myocardial infarction (MI, N=5199) were recruited to study the association between single nucleotide polymorphisms (SNPs) within SRD5A1, SRD5A2, and AKR1C3 and incident MI using Cox regression models. Significant results were replicated within the Atherosclerosis Risk in Communities cohort and the second cohort of the RSII. ResultsThe expression of SRD5A1, AKR1C3, and AR was found in all myocardial samples, whereas HSD17B3 and SRD5A2 expression levels were low and undetectable, respectively. Myocardial SRD5A1 expression was higher in women than in men. Within SRD5A1, SNP rs248805G>A was significantly associated with incident MI in western European women (hazard ratio 1.49; 95% confidence interval 1.19–1.87). This SNP is tightly linked to the HinfI polymorphism in SRD5A1 (rs248793G>C), of which the minor allele has been associated with a higher DHT/T ratio. ConclusionGenetic variation in SRD5A1 is associated with an increased risk of MI in western European women, possibly because of the sex-specific potential of local androgen conversion and effect.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"2 3 1","pages":"134–141"},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89325781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Testosterone and cardiovascular disease: controversy or wake-up call? 睾酮和心血管疾病:争论还是警钟?

Cardiovascular endocrinology Pub Date : 2014-12-01 DOI: 10.1097/XCE.0000000000000038

K. Yuen

{"title":"Testosterone and cardiovascular disease: controversy or wake-up call?","authors":"K. Yuen","doi":"10.1097/XCE.0000000000000038","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000038","url":null,"abstract":"In men with hypogonadism due to diseases of the hypothalamus, pituitary, or testis, testosterone therapy is generally safe and has been shown to induce beneficial effects. Conversely, in men with age-related low testosterone levels, the significance of this change and the effects of testosterone therapy are debatable. Studies have linked low testosterone levels with increased cardiovascular morbidity and mortality, with testosterone therapy being reported to improve cardiovascular risk profiles. However, two recent retrospective studies have fueled the controversy on testosterone therapy by reporting increased cardiovascular events. Because placebo-controlled, randomized clinical trials on testosterone therapy in older men with age-related decline in testosterone levels are lacking, long-term cardiovascular health following testosterone therapy in this patient population remains unclear. Therefore, a careful approach should be adopted when considering therapy of hypogonadism and coexisting cardiovascular disease in older men. Adequately powered, long-term prospective randomized trials on testosterone in older men are urgently needed. Cardiovasc Endocrinol 00:000–000 © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"87 1","pages":"117-122"},"PeriodicalIF":0.0,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82160591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4